Sarah Guégan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah Guégan has a total of 345 co-authors. Here are the top co-authors by number of shared publications:
- Selim Aractingi
Department of Dermatology, CERTIM Group, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, 123 Bd Port-Royal, 75 679, Paris Cedex 14, France
15 shared publications Philippe Moguelet
Department of Pathology Tenon University Hospital, AP‐HP Paris France
7 shared publications- Kiarash Khosrotehrani
Dermatology Research Centre, Frazer Institute The University of Queensland Brisbane Australia
6 shared publications - Nicolas Dupin
Dermatology Department Cochin Hospital Paris France
6 shared publications - Romain H. Fontaine
Saint Antoine Research Center, U938, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France; Université Pierre et Marie Curie-Paris VI, Paris, France
4 shared publications Arnaud Picard
Université René Descartes-Paris V, Paris, France
3 shared publications
Latest Publications
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- Open Access
Spatially resolved diversity in molecular states underlies congenital melanocytic nevi and associated tumors
The congenital melanocytic nevus (CMN) is a developmental skin disorder characterized by prenatal melanocyte overgrowth, exhibiting heterogeneity in surface size, depth, and clinical behavior. Large/giant CMN carry an elevated, anticipatory melanoma risk relative to more common, small CMN. However, deeper insights into melanocytic states, genomic and epigenomic alterations, and microenvironmental cues governing disease progression are needed to predict lesions disposed to transformation. Although large/giant CMN melanocyte heterogeneity was recently established, spatial organization of these states and their niche interactions are unknown. Using advanced spatial and single-cell transcriptomics and bulk methylomics, we characterized ten CMN, seven CMN-associated proliferative nodules and three clinically diagnosed melanomas arising in CMN from children, integrating data from healthy skin references to contextualize melanocyte states in situ . CMN-specific melanocytic states, distinct in differentiation and proliferation, were spatially stratified, with immature melanocytes in deep dermis and more differentiated melanocytes approaching the epidermis. We then constructed a robust atlas of CMN cellular states by integrating single-cell transcriptomic data from five new large/giant CMN with published datasets, using it to deconvolute the spatial information. Cell–cell communication inference uncovered enhanced signaling (e.g. pleiotrophin, IGF1, periostin, semaphorin pathways) between CMN melanocytes, fibroblasts, and hair follicle–associated cells. Analysis of CMN-derived tumors, including longitudinal cases with ≥2 samples, revealed divergent spatial melanocytic transcription distinguishing immune-enriched lesions from tumors with oncogenic/pro-invasive signatures. Collectively, these findings establish a spatially resolved framework linking melanocyte heterogeneity, signaling, and genomic instability in CMN, providing mechanistic insights to refine risk stratification and prognosis for CMN-associated tumors.
Open AccessSpatially resolved diversity in molecular states underlies congenital melanocytic nevi and associated tumors
The congenital melanocytic nevus (CMN) is a developmental skin disorder characterized by prenatal melanocyte overgrowth, exhibiting heterogeneity in surface size, depth, and clinical behavior. Large/giant CMN carry an elevated, anticipatory melanoma risk relative to more common, small CMN. However, deeper insights into melanocytic states, genomic and epigenomic alterations, and microenvironmental cues governing disease progression are needed to predict lesions disposed to transformation. Although large/giant CMN melanocyte heterogeneity was recently established, spatial organization of these states and their niche interactions are unknown. Using advanced spatial and single-cell transcriptomics and bulk methylomics, we characterized ten CMN, seven CMN-associated proliferative nodules and three clinically diagnosed melanomas arising in CMN from children, integrating data from healthy skin references to contextualize melanocyte states in situ . CMN-specific melanocytic states, distinct in differentiation and proliferation, were spatially stratified, with immature melanocytes in deep dermis and more differentiated melanocytes approaching the epidermis. We then constructed a robust atlas of CMN cellular states by integrating single-cell transcriptomic data from five new large/giant CMN with published datasets, using it to deconvolute the spatial information. Cell–cell communication inference uncovered enhanced signaling (e.g. pleiotrophin, IGF1, periostin, semaphorin pathways) between CMN melanocytes, fibroblasts, and hair follicle–associated cells. Analysis of CMN-derived tumors, including longitudinal cases with ≥2 samples, revealed divergent spatial melanocytic transcription distinguishing immune-enriched lesions from tumors with oncogenic/pro-invasive signatures. Collectively, these findings establish a spatially resolved framework linking melanocyte heterogeneity, signaling, and genomic instability in CMN, providing mechanistic insights to refine risk stratification and prognosis for CMN-associated tumors.
- 12 November 2025
- Published by Elsevier in Annales de Chirurgie Plastique Esthétique
- Vol. 70 (6) , 457-460
Carcinome épidermoïde cutané
- 12 November 2025
- Published by Elsevier in Annales de Chirurgie Plastique Esthétique
- Vol. 70 (6) , 457-460
Carcinome épidermoïde cutané
- 24 October 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (4) , 479-490
Genetic landscape of non‐ UV ‐induced cutaneous squamous cell carcinomas
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is most often caused by cumulative UV exposure. However, cSCC may also arise independently of UV exposure, on sites of sustained skin damage like chronic ulcers, scars, Recessive Dystrophic Epidermolysis Bullosa (RDEB), and inflammatory skin diseases such as hidradenitis suppurativa (HS). Little is known about non‐UV‐induced skin carcinomas. We aimed to describe the clinical, pathological, and genetic features, of non‐UV‐induced cSCC. We collected clinical and pathologic data corresponding to 31 patients with non‐UV‐induced cSCC, including 5 cSCC on HS, 4 on chronic leg ulcers and 8 on RDEB. DNA was extracted from FFPE samples and analysed using a NGS assay targeting 523 cancer genes. A comparison was performed with published genetic data obtained in non‐UV‐induced and UV‐induced cSCC. We found that the Tumour Mutational Burden (TMB) of non‐UV‐induced cSCC was 6‐times lower than the published TMB of UV‐induced cSCC. The predominant mutational signature was a clock‐wise signature. By comparing the frequency of driver mutations, we found TP53 and NOTCH1 to be significantly less frequently mutated than in UV‐mutated cSCC. Interestingly, KMT2B (a histone methyl transferase) was mutated in 11/31 non‐UV‐induced cSCC and this proportion was significantly higher than in UV‐mutated cSCC. These mutations were high impact loss‐of‐function mutations. We found that knocking down KMT2B expression using siRNA did not affect cell proliferation of SCC‐13 and A‐431 cell lines, however, it significantly increased cell migration in vitro . Taken together, this study provides a comprehensive description of non‐UV‐induced cSCC and identifies that KMT2B is mutated and involved in non‐UV‐induced cSCC carcinogenesis. © 2025 The Pathological Society of Great Britain and Ireland.
- 24 October 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (4) , 479-490
Genetic landscape of non‐ UV ‐induced cutaneous squamous cell carcinomas
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is most often caused by cumulative UV exposure. However, cSCC may also arise independently of UV exposure, on sites of sustained skin damage like chronic ulcers, scars, Recessive Dystrophic Epidermolysis Bullosa (RDEB), and inflammatory skin diseases such as hidradenitis suppurativa (HS). Little is known about non‐UV‐induced skin carcinomas. We aimed to describe the clinical, pathological, and genetic features, of non‐UV‐induced cSCC. We collected clinical and pathologic data corresponding to 31 patients with non‐UV‐induced cSCC, including 5 cSCC on HS, 4 on chronic leg ulcers and 8 on RDEB. DNA was extracted from FFPE samples and analysed using a NGS assay targeting 523 cancer genes. A comparison was performed with published genetic data obtained in non‐UV‐induced and UV‐induced cSCC. We found that the Tumour Mutational Burden (TMB) of non‐UV‐induced cSCC was 6‐times lower than the published TMB of UV‐induced cSCC. The predominant mutational signature was a clock‐wise signature. By comparing the frequency of driver mutations, we found TP53 and NOTCH1 to be significantly less frequently mutated than in UV‐mutated cSCC. Interestingly, KMT2B (a histone methyl transferase) was mutated in 11/31 non‐UV‐induced cSCC and this proportion was significantly higher than in UV‐mutated cSCC. These mutations were high impact loss‐of‐function mutations. We found that knocking down KMT2B expression using siRNA did not affect cell proliferation of SCC‐13 and A‐431 cell lines, however, it significantly increased cell migration in vitro . Taken together, this study provides a comprehensive description of non‐UV‐induced cSCC and identifies that KMT2B is mutated and involved in non‐UV‐induced cSCC carcinogenesis. © 2025 The Pathological Society of Great Britain and Ireland.
- Open Access
- 1 January 2025
- Published by Elsevier in SSRN Electronic Journal
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA
Background Cemiplimab an anti-programmed cell death receptor-1 antibody, was approved by the FDA and EMA for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) ineligible for curative surgery/radiotherapy or with metastatic (m) CSCC. TOSCA study evaluated the real-world effectiveness and safety of cemiplimab compared to historical systemic therapies (HSTs). Methods TOSCA (NCT05302297) was a large French retrospective, multicenter study comparing patient with la/mCSCC treated with cemiplimab via the early access program (EAP, 2018–2019) or HST (2013–2018). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall response rate (ORR), and safety. Effectiveness analysis using inverse probability weighting included a trial-like cohort of only immunocompetent patients meeting the EAP criteria to emulate a randomized clinical trial; safety analysis included all real-life patients. Findings The study included 280 real-life patients (cemiplimab: n=147; HST: n=133). The primary effectiveness analysis included a trial-like cohort (cemiplimab: n=129; HST: n=70; median age: 81 and 78 years, respectively). Median follow-up was 20 and 10 months in the cemiplimab and HST arms, respectively; median OS was 21.2 and 9.8 months, respectively (HR 95% CI: 0.57 [0.45–0.73]; P<0.0001); median PFS was 13.7 and 5.3 months, respectively (HR [95% CI]: 0.57 [0.43–0.76]; P=0.0001). Adverse drug reactions occurred in 27% of cemiplimab patients and 33% of HST patients. . Interpretation TOSCA demonstrated better survival and response outcomes for cemiplimab versus HST in la/mCSCC; emphasizing, the importance of rigorous retrospective studies in the absence of standard comparative trials. Funding Sanofi.
- 1 January 2025
- Published by Elsevier in SSRN Electronic Journal
Open AccessCemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA
Background Cemiplimab an anti-programmed cell death receptor-1 antibody, was approved by the FDA and EMA for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) ineligible for curative surgery/radiotherapy or with metastatic (m) CSCC. TOSCA study evaluated the real-world effectiveness and safety of cemiplimab compared to historical systemic therapies (HSTs). Methods TOSCA (NCT05302297) was a large French retrospective, multicenter study comparing patient with la/mCSCC treated with cemiplimab via the early access program (EAP, 2018–2019) or HST (2013–2018). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall response rate (ORR), and safety. Effectiveness analysis using inverse probability weighting included a trial-like cohort of only immunocompetent patients meeting the EAP criteria to emulate a randomized clinical trial; safety analysis included all real-life patients. Findings The study included 280 real-life patients (cemiplimab: n=147; HST: n=133). The primary effectiveness analysis included a trial-like cohort (cemiplimab: n=129; HST: n=70; median age: 81 and 78 years, respectively). Median follow-up was 20 and 10 months in the cemiplimab and HST arms, respectively; median OS was 21.2 and 9.8 months, respectively (HR 95% CI: 0.57 [0.45–0.73]; P<0.0001); median PFS was 13.7 and 5.3 months, respectively (HR [95% CI]: 0.57 [0.43–0.76]; P=0.0001). Adverse drug reactions occurred in 27% of cemiplimab patients and 33% of HST patients. . Interpretation TOSCA demonstrated better survival and response outcomes for cemiplimab versus HST in la/mCSCC; emphasizing, the importance of rigorous retrospective studies in the absence of standard comparative trials. Funding Sanofi.
- 11 March 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (3) , 101371
β-Lactam allergy management: A practical approach for clinical decision-making
- 11 March 2024
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 43 (3) , 101371
β-Lactam allergy management: A practical approach for clinical decision-making
- 1 January 2022
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 103 (1) , 41-48
Abdominal metastases from Merkel cell carcinoma: Prevalence and presentation on CT examination in 111 patients
- 1 January 2022
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 103 (1) , 41-48
Abdominal metastases from Merkel cell carcinoma: Prevalence and presentation on CT examination in 111 patients
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A155
Réactions cutanées rares aux vaccins contre la COVID-19 : série de cas monocentrique et revue de la littérature
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A155
Réactions cutanées rares aux vaccins contre la COVID-19 : série de cas monocentrique et revue de la littérature
- 1 November 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (11) , 697-698
Immune checkpoint inhibitor-induced hypophysitis
- 1 November 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (11) , 697-698
Immune checkpoint inhibitor-induced hypophysitis
- Open Access
- 7 August 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (12) , E847-E850
Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature
- 7 August 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (12) , E847-E850
Open AccessRare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature